Cost-effectiveness of moderate-to-severe psoriasis treatment
- 24 January 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 7 (2) , 157-167
Abstract
(2006). Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opinion on Pharmacotherapy: Vol. 7, No. 2, pp. 157-167.Keywords
This publication has 38 references indexed in Scilit:
- Have Methotrexate-Induced Liver Fibrosis and Cirrhosis Become Rare?Dermatology, 2005
- Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trialJournal of the American Academy of Dermatology, 2005
- Diagnosis and treatment of psoriatic arthritisJournal of the American Academy of Dermatology, 2005
- Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert PanelJournal of Cutaneous Medicine and Surgery, 2004
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004
- T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of ActionDermatology, 2004
- AAD consensus statement on psoriasis therapiesJournal of the American Academy of Dermatology, 2003
- Therapeutic photoimmunology: photoimmunological mechanisms in photo (chemo) therapyJournal of Photochemistry and Photobiology B: Biology, 1998
- The annual cost of psoriasisJournal of the American Academy of Dermatology, 1993
- Cutaneous Squamous-Cell Carcinoma in Patients Treated with PUVANew England Journal of Medicine, 1984